Other Non-Current Liabilities
Moderna Other Non-Current Liabilities decreased by 0.7% to $283.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.3%, from $274.00M to $283.00M. Over 5 years (FY 2020 to FY 2025), Other Non-Current Liabilities shows an upward trend with a 148.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
How to read this metric
An increase may indicate rising long-term operational risks or deferred tax burdens, while a decrease suggests the settlement of these obligations.
Detailed definition
This represents miscellaneous long-term obligations that do not fit into standard categories like long-term debt or pens...
Peer comparison
Peers in the medical device and pharmaceutical sectors often hold similar balances related to deferred tax liabilities and long-term environmental or legal accruals.
other_non_current_liabilitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00M | $1.00M | $76.00M | $91.00M | $113.00M | $81.00M | $135.00M | $163.00M | $173.00M | $172.00M | $256.00M | $262.00M | $266.00M | $276.00M | $267.00M | $274.00M | $276.00M | $281.00M | $285.00M | $283.00M |
| QoQ Change | — | +0.0% | >999% | +19.7% | +24.2% | -28.3% | +66.7% | +20.7% | +6.1% | -0.6% | +48.8% | +2.3% | +1.5% | +3.8% | -3.3% | +2.6% | +0.7% | +1.8% | +1.4% | -0.7% |
| YoY Change | — | — | — | — | >999% | >999% | +77.6% | +79.1% | +53.1% | +112.3% | +89.6% | +60.7% | +53.8% | +60.5% | +4.3% | +4.6% | +3.8% | +1.8% | +6.7% | +3.3% |
Other Non-Current Liabilities at Other Companies
Frequently Asked Questions
- What is Moderna's other non-current liabilities?
- Moderna (MRNA) reported other non-current liabilities of $283.00M in Q1 2026.
- How has Moderna's other non-current liabilities changed year-over-year?
- Moderna's other non-current liabilities increased by 3.3% year-over-year, from $274.00M to $283.00M.
- What is the long-term trend for Moderna's other non-current liabilities?
- Over 5 years (2020 to 2025), Moderna's other non-current liabilities has grown at a 148.6% compound annual growth rate (CAGR), from $3.00M to $285.00M.
- What does other non-current liabilities mean?
- Miscellaneous long-term financial obligations not classified under standard debt or liability categories.